Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Antibodies, Monoclonal (1):
Recent article
Antibodies, Monoclonal
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
New England Journal of Medicine (365)14 2011
Abstract
We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.
We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus...
|
PMID: 21991949
PDF is available here.
PDF is available here.
Cytotherapy (13)9 2011
Abstract
We studied the combined effect of MSC and IBD drugs in in vitro functionality assays.
The effects of azathioprine, methotrexate, 6-mercaptopurine and anti-tumor necrosis factor (TNF)-α on MSC phenotype, survival, differentiation capacity and immunosuppressive capacity were studied....
|
PMID: 21846292
PDF is available here.
PDF is available here.
Abstract
We also observed synergic co-inhibition of the cell cycle of SK-OV-3 in the S phase.
We conclude that CH12 antibody is a promising candidate for clinical therapy for ovarian cancer cells, which has lower sensitivity to cisplatin treatment; however, the underlying mechanism needs furt...
|
PMID: 21809030
PDF is available here.
PDF is available here.
New England Journal of Medicine (365)13 2011
Abstract
New England Journal of Medicine (365)13 2011
Abstract
New England Journal of Medicine (365)13 2011
Abstract
Abstract
This paper in the series from the World Congress of Gastroenterology addresses the safety and immunogenicity of biological therapy. The safety profile in randomized controlled studies of all biological agents in Crohn's disease (CD) and ulcerative colitis has been generally favorable...
|
PMID: 21844919
PDF is available here.
PDF is available here.
Abstract
This paper in the series from the World Congress of Gastroenterology addresses the safety and immunogenicity of biological therapy. The safety profile in randomized controlled studies of all biological agents in Crohn's disease (CD) and ulcerative colitis has been generally favorable...
|
PMID: 21844919
PDF is available here.
PDF is available here.
Abstract
We found a very high number of patients who developed antinuclear autoantibodies (16 of 24 (66.6%) at the time of infliximab discontinuation) and anti-ds-DNA autoantibodies (12 of 24 (50%) at the time of infliximab discontinuation). However, in most of these patients they had no clinical significanc...
|
PMID: 21933639
PDF is available here.
PDF is available here.
Abstract
B-cell-directed therapy-the use of agents that eliminate B cells or block cytokines important for B-cell function-is emerging as a promising approach to the treatment of rheumatic disease. Target diseases, including systemic lupus erythematosus (SLE), display diverse patterns of auto...
|
PMID: 21808289
PDF is available here.
PDF is available here.
Abstract
Abstract
Abstract
Abstract
A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC).
Patients were treated with bevacizum...
|
PMID: 21815133
PDF is available here.
PDF is available here.
Abstract
Abstract
Despite large-scale efforts devoted to the conduct of clinical trials in systemic lupus erythematosus (SLE), no new therapy has been approved for treatment of this disease in more than 50 years. Increased understanding of the immunologic mechanisms underlying SLE has led to the devel...
|
PMID: 21584692
PDF is available here.
PDF is available here.
Abstract
Non-response, loss of response, or intolerance to anti-tumour necrosis factor alpha (anti-TNFα) therapy is well recognised in Crohn's disease (CD) patients. Data concerning outcomes following the use of a second anti-TNFα therapy, particularly in patients who do not respond to a fi...
|
PMID: 21683302
PDF is available here.
PDF is available here.
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology (27)8 2011
Abstract
To prepare anti-B7-H4 monoclonal antibodies (mAbs) and to characterize their biological functions.
A human B7-H4 transfectant cell line L929/B7-H4 was used as an immunogen to immunize BALB/c mice. By means of the B lymphoma hybridoma technique, immunofluorescent cytom...
|
PMID: 21806888
PDF is available here.
PDF is available here.
Seminars in Oncology (38)4 2011
Abstract
Colorectal cancer represents a major public health problem due to its frequency and mortality rate. Adjuvant chemotherapy has improved the prognosis of colon cancer. Six months of oxaliplatin and fluoropyrimidine in combination is the standard adjuvant treatment in stage III patients...
|
PMID: 21810511
PDF is available here.
PDF is available here.
Bulletin du cancer (98)8 2011
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice of hematologic malignancies. Acute graft versus host disease (GvHD) is common after HSCT and directly related to graft versus leukemia effect. Little progress has been done in the treatment of acute...
|
PMID: 21835730
PDF is available here.
PDF is available here.
Abstract
We developed a monoclonal antibody (mAb) against the extracellular domain of B7-H4 through immunization of Balb/c mice with 3T3-mB7-H4 cells which expressed extrinsic B7-H4. A stable hybridoma cell line was established. Then, we analysed the characterization of the mAb through Enzyme linked immunoso...
|
PMID: 21813370
PDF is available here.
PDF is available here.
New Microbiologica (34)3 2011
Abstract
We successfully generated a mouse monoclonal antibody fragment from a phage display library directed against protein E7 of HPV18 avoiding antigen purification as for immunizing mice as for antibody library selection. Our work demonstrates the feasibility of phage antibody selections on antigens tran...
|
PMID: 21811748
PDF is available here.
PDF is available here.
Abstract
We show that [(3)H]-resveratrol enters colon cancer cells (SW480, SW620, HT29) and leukemia U937 cells through a monensin (5-20 μmol/L) -sensitive process that suggests clathrin-independent endocytosis. Uptake of the molecule can be prevented by methyl-β-cyclodextrin (2-12 mg/mL), nystatin (12 ng/...
|
PMID: 21467134
PDF is available here.
PDF is available here.
Abstract
Our results underscore the value of genotyping in the clinical trial setting to avoid misinterpretations that could lead to terminating development of a promising new agent....
|
PMID: 21412181
PDF is available here.
PDF is available here.
New England Journal of Medicine (364)26 2011
Abstract
The Lancet (377)9783 2011
Abstract
Epileptic Disorders (13)2 2011
Abstract
We describe a patient who acutely developed seizures temporally related to infliximab treatment, which disappeared after drug withdrawal. MRI showed encephalopathy involving mainly cortical regions and EEGs showed focal paroxysmal activity which completely disappeared a few days after infliximab wit...
|
PMID: 21636356
PDF is available here.
PDF is available here.
Abstract
A number of therapeutic agents are available for the treatment of asthma, including inhaled corticosteroids, long- and short-acting beta-agonists, leukotriene-modifying agents, long- and short-acting anticholinergic agents, chromones, theophylline, allergen immunotherapy, and oral co...
|
PMID: 21393345
PDF is available here.
PDF is available here.
Abstract
Infliximab is a chimerical monoclonal antibody that inhibits pro-inflammatory activity of tumour-necrosis factor alpha (TNFα) and it is the primary biological agent used in the treatment of moderate-to-severe ulcerative colitis (UC). We report a case of vitiligo following infliximab...
|
PMID: 21684486
PDF is available here.
PDF is available here.
Abstract
First-line treatment with bevacizumab combined with chemotherapy has been shown to improve outcomes in patients with advanced, nonsquamous non-small cell lung cancer (NSNSCLC) in phase III clinical trials. SAiL (MO19390), an open-label, multicenter, single-arm study, evaluated the sa...
|
PMID: 21512405
PDF is available here.
PDF is available here.
Revue medicale suisse (7)296 2011
Abstract
We will cover the results obtained with targeted therapies such as "tyrosin kinase inhibitors" (TKI), as well as those obtained with a monoclonal antibody directed against the CTLA-4 receptor of lymphocytes....
|
PMID: 21721201
PDF is available here.
PDF is available here.
New England Journal of Medicine (364)20 2011
Abstract
We randomly assigned patients to receive alemtuzumab or conventional induction therapy (basiliximab or rabbit antithymocyte globulin). Patients were stratified according to acute rejection risk, with a high risk defined by a repeat transplant, a peak or current value of panel-reactive antibodies of...
|
PMID: 21591943
PDF is available here.
PDF is available here.
New England Journal of Medicine (364)20 2011
Abstract
Abstract
Monoclonal antibodies have emerged as a new class of agents causing drug-related pulmonary involvement in patients with systemic rheumatologic autoimmune diseases. The most frequently associated noninfectious pulmonary diseases are interstitial pneumonia (118 cases reported by August 2010), sarcoid-l...
|
PMID: 21531225
PDF is available here.
PDF is available here.
Xenobiotica (41)5 2011
Abstract
Monoclonal antibodies (mabs) are powerful tools for the quantification, detection, and targeting of specific molecules. Allergen-specific mabs are important for the quantification of major allergens in allergen preparations used for allergen-specific immunotherapy and allergy diagnosis. Indeed, prog...
|
PMID: 18612608
PDF is available here.
PDF is available here.
Xenobiotica (41)5 2011
Abstract
One of the most important structural features of recombinant monoclonal antibodies produced in mammalian cells is the N-linked oligosaccharide profile. These profiles impact recombinant therapeutics in a multitude of ways affecting distribution, efficacy, and immunogenicity. High mannose, alpha-gal...
|
PMID: 18373268
PDF is available here.
PDF is available here.
Xenobiotica (41)5 2011
Abstract
A number of HPLC and mass spectrometric techniques are used to characterize post-translational modification in recombinant monoclonal antibodies (MAbs) using the intact glycoprotein and free glycans. LC separation utilizing fluorescent detection technique allows tentative structural assignment of MA...
|
PMID: 18373269
PDF is available here.
PDF is available here.
Abstract
Over the past decade, the use of the monoclonal antibody alemtuzumab in chronic lymphocytic leukemia has expanded from administration as a single-agent therapy, into use in combination with fludarabine or rituximab, and further to use as a consolidation agent with the goal of eradica...
|
PMID: 21685865
PDF is available here.
PDF is available here.
Abstract
To explore the expression of mycoplasma monoclonal antibody PD4 in different laryngeal carcinoma tissues and their clinical significance.
|
PMID: 21809556
PDF is available here.
PDF is available here.
Abstract